CA2882621A1 - Method for determining breast cancer treatment - Google Patents

Method for determining breast cancer treatment Download PDF

Info

Publication number
CA2882621A1
CA2882621A1 CA2882621A CA2882621A CA2882621A1 CA 2882621 A1 CA2882621 A1 CA 2882621A1 CA 2882621 A CA2882621 A CA 2882621A CA 2882621 A CA2882621 A CA 2882621A CA 2882621 A1 CA2882621 A1 CA 2882621A1
Authority
CA
Canada
Prior art keywords
breast cancer
androgen
tissue sample
determining
enzalutamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2882621A
Other languages
English (en)
French (fr)
Inventor
Jennifer Richer Mouchantat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Colorado Springs
Original Assignee
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Colorado Springs filed Critical University of Colorado Colorado Springs
Publication of CA2882621A1 publication Critical patent/CA2882621A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2882621A 2012-08-23 2013-03-15 Method for determining breast cancer treatment Abandoned CA2882621A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261692331P 2012-08-23 2012-08-23
US61/692,331 2012-08-23
PCT/US2013/031812 WO2014031164A1 (en) 2012-08-23 2013-03-15 Method for determining breast cancer treatment

Publications (1)

Publication Number Publication Date
CA2882621A1 true CA2882621A1 (en) 2014-02-27

Family

ID=50150282

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2882621A Abandoned CA2882621A1 (en) 2012-08-23 2013-03-15 Method for determining breast cancer treatment

Country Status (7)

Country Link
US (2) US10175240B2 (OSRAM)
EP (1) EP2888594B1 (OSRAM)
JP (1) JP6153613B2 (OSRAM)
AU (1) AU2013306380A1 (OSRAM)
CA (1) CA2882621A1 (OSRAM)
ES (1) ES2696202T3 (OSRAM)
WO (1) WO2014031164A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103997894B (zh) 2011-07-29 2016-08-24 麦迪韦逊前列腺治疗股份有限公司 乳癌的治疗
EP2888594B1 (en) 2012-08-23 2018-08-15 The Regents of the University of Colorado, a body corporate Method for determining breast cancer treatment
CA2970469A1 (en) 2014-12-12 2016-06-16 Amy Christian Peterson Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
CN113490850B (zh) * 2018-08-17 2024-12-06 基因泰克公司 用于治疗乳腺癌的诊断和治疗方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008185A (en) * 1985-11-04 1991-04-16 Cell Analysis Systems, Inc. Methods and apparatus for the quantitation of nuclear proteins
US5292638A (en) 1990-12-07 1994-03-08 The Regents Of The University Of California Method of determining functional estrogen receptors for prognosis of cancer
AU8821301A (en) * 2000-06-28 2002-01-08 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, design and use
CA2647743A1 (en) * 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection of steroid receptors on circulating carcinoma cells and treatment
JP2010500577A (ja) * 2006-08-07 2010-01-07 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 癌の予後および予測シグナチャーのプロテオミクスパターン
EP2065474A1 (en) * 2007-11-28 2009-06-03 Siemens Healthcare Diagnostics GmbH A method to assess prognosis and to predict therapeutic response to endocrine treatment
US20100029734A1 (en) 2008-05-06 2010-02-04 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
EP2888594B1 (en) 2012-08-23 2018-08-15 The Regents of the University of Colorado, a body corporate Method for determining breast cancer treatment

Also Published As

Publication number Publication date
US20150253329A1 (en) 2015-09-10
US20190113515A1 (en) 2019-04-18
AU2013306380A1 (en) 2015-03-05
US10175240B2 (en) 2019-01-08
JP6153613B2 (ja) 2017-06-28
WO2014031164A1 (en) 2014-02-27
JP2015529327A (ja) 2015-10-05
EP2888594A1 (en) 2015-07-01
EP2888594B1 (en) 2018-08-15
EP2888594A4 (en) 2016-04-20
US11221334B2 (en) 2022-01-11
ES2696202T3 (es) 2019-01-14

Similar Documents

Publication Publication Date Title
Cochrane et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
US11221334B2 (en) Method for determining breast cancer treatment
Siersbæk et al. Signaling pathways and steroid receptors modulating estrogen receptor α function in breast cancer
Isikbay et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer
Basile et al. Androgen receptor in estrogen receptor positive breast cancer: Beyond expression
Madeo et al. Nuclear alternate estrogen receptor GPR30 mediates 17β-estradiol–induced gene expression and migration in breast cancer–associated fibroblasts
Dressing et al. Membrane progesterone receptors (mPRs) mediate progestin induced antimorbidity in breast cancer cells and are expressed in human breast tumors
Anbalagan et al. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer
Nickkho-Amiry et al. Peroxisome proliferator–activated receptors modulate proliferation and angiogenesis in human endometrial carcinoma
Chia et al. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer
Mishra et al. Leptin signals via TGFB1 to promote metastatic potential and stemness in breast cancer
Delgado-Rosas et al. The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis
Barakat et al. CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells
Zarrinpashneh et al. Ablation of SGK1 impairs endothelial cell migration and tube formation leading to decreased neo-angiogenesis following myocardial infarction
Ravaioli et al. Androgen receptor in breast cancer: The “5W” questions
Thanopoulou et al. Hormonal therapy in gynecological sarcomas
Bilandzic et al. Betaglycan blocks metastatic behaviors in human granulosa cell tumors by suppressing NFκB-mediated induction of MMP2
Lan et al. Downregulation of β-arrestin 1 suppresses glioblastoma cell malignant progression vis inhibition of Src signaling
Huang et al. Intracellular and extracellular S100A9 trigger epithelial-mesenchymal transition and promote the invasive phenotype of pituitary adenoma through activation of AKT1
Luo et al. Dynamic monitoring of GPER-mediated estrogenic effects in breast cancer associated fibroblasts: an alternative role of estrogen in mammary carcinoma development
Cavalloni et al. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas
Dotto et al. Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities
Eritja et al. Combinatorial therapy using dovitinib and ICI182. 780 (fulvestrant) blocks tumoral activity of endometrial cancer cells
Liang et al. Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells
US20250281509A1 (en) Sequential hormone therapy to improve survival and enhance response to immune therapy in men with prostate cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180309

FZDE Discontinued

Effective date: 20210831